Results 21 to 30 of about 21,108 (240)

A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes

Frontiers in Endocrinology, 2022
BackgroundMost patients with type 1 diabetes (T1DM) do not reach the blood glucose goal with treatment of insulin. In our research, we intended to estimate the therapeutic effect and safety of additional different doses of dapagliflozin on insulin ...
Yinhui Li, Hui Li, Liming Dong, Dandan Lin, Lijuan Xu, Pengwei Lou, Deng Zang, Kai Wang, Li Ma   +8 more
doaj   +1 more source

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin. [PDF]

, 2023
AIMS Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid ...
Windecker, Stephan, Benedikt Bernhard, Thomas Pilgrim, Asatryan, Babken, Christoph Gräni, Lukas Hunziker, Stortecky, Stefan, Dobner, Stephan, Stephan Windecker, Bernhard, Benedikt, Stephan Dobner, Pilgrim, Thomas, Hunziker, Lukas, Babken Asatryan, Gräni, Christoph, Stefan Stortecky   +15 more
core   +2 more sources

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy

Frontiers in Cardiovascular Medicine, 2022
Background: The sodium-glucose co-transporter-2 (SGLT-2) inhibitor dapagliflozin improves cardiovascular outcomes in patients with type 2 diabetes in a manner that is partially independent of its hypoglycemic effect.
Yong-Wei Yu, Yong-Wei Yu, Jia-Qun Que, Shuai Liu, Kai-Yu Huang, Lu Qian, Ying-Bei Weng, Fang-Ning Rong, Lei Wang, Ying-Ying Zhou, Yang-Jing Xue, Kang-Ting Ji   +11 more
doaj   +1 more source

Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity

Molecules, 2020
Dapagliflozin, empagliflozin, tofogliflozin, selective inhibitors of sodium-glucose cotransporter 2 (SGLT2), is used clinically to reduce circulation glucose levels in patients with type 2 diabetes mellitus by blocking the reabsorption of glucose by the ...
Junichi Okada, Eijiro Yamada, Tsugumichi Saito, Hideaki Yokoo, Aya Osaki, Yoko Shimoda, Atsushi Ozawa, Yasuyo Nakajima, Jeffrey E. Pessin, Shuichi Okada, Masanobu Yamada   +10 more
doaj   +1 more source

Dapagliflozin Mitigated Elevated Disomic and Diploid Sperm in a Mouse Model of Diabetes and Recover the Disrupted Ogg1, Parp1, and P53 Gene Expression

Biomedicines, 2023
Increases in numerical chromosomal syndromes were observed in children of diabetic mothers. However, the effects of diabetes on male reproduction, specifically numerical chromosomal aberrations (aneuploidy), have not been studied.
Norah A. Albekairi, Mohammed A. Al-Hamamah, Ali A. Alshamrani, Mohamed S. M. Attia, Ahmed Nadeem, Mushtaq A. Ansari, Sheikh F. Ahmad, Saleh A. Bakheet, Sabry M. Attia   +8 more
doaj   +1 more source

Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway

Frontiers in Pharmacology, 2021
As a newly approved oral hypoglycaemic agent, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin, which is derived from the natural product phlorizin can effectively reduce blood glucose.
Liuran Li, Qinghua Li, Wenbin Huang, Yibing Han, Huiting Tan, Min An, Qianru Xiang, Rui Zhou, Li Yang, Li Yang, Yanzhen Cheng   +10 more
doaj   +1 more source

Dapagliflozin and Anemia in Patients with Chronic Kidney Disease [PDF]

, 2023
BackgroundIn the DAPA-CKD (Dapagliflozin in Patients with Chronic Kidney Disease) trial, dapagliflozin improved kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) with or without type 2 diabetes (T2D).
Heerspink, Hiddo J L, Correa-Rotter, Ricardo, Meir Schechter, Anna Maria Langkilde, Isidto, Rey, Kashihara, Naoki, Chertow, Glenn M, Jose Luis Górriz, Jongs, Niels; id_orcid, Naoki Kashihara, Robert D. Toto, Górriz, Jose Luis, Toto, Robert D, Akihiko Koshino, Wheeler, David C, Rossing, Peter, Vart, Priya, Koshino, Akihiko; id_orcid, Koshino, Akihiko, McMurray, John J V, Langkilde, Anna Maria, John J.V. McMurray, Jongs, Niels, Peter Rossing, Hiddo J.L. Heerspink, Rey Isidto, David C. Wheeler, Glenn M. Chertow, Priya Vart, Schechter, Meir, Ricardo Correa-Rotter, Niels Jongs   +31 more
core   +4 more sources

Dapagliflozin – do we need it registered for type 2 diabetes? [PDF]

, 2014
INTRODUCTION: \ud \ud Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) promote the excretion of glucose to reduce glycated hemoglobin (HbA1c) levels.
Tuli, Rinku, Doggrell, Sheila A.
core   +1 more source

Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice [PDF]

, 2017
This study assessed the metabolic and neuroprotective actions of the sodium glucose co-transporter-2 inhibitor dapagliflozin in combination with the GLP-1 agonist liraglutide in dietary-induced diabetic mice.
Bjourson, Anthony, Gault, V.A., Pathak, Varun, Varun Pathak, Maurice O’Kane, Pathak, V., Moffett, R Charlotte, Peter R Flatt, Vadivel Parthsarathy, Flatt, Peter R., Gault, Victor A., Moffett, R.C., Millar, P., Victor A Gault, Paul Millar, Bjourson, A.J., Flatt, P.R., Parthsarathy, Vadivel, Millar, Paul, O'Kane, Maurice, Pathak, Nupur M, Flatt, Peter R, Nupur Pathak, Anthony J Bjourson, Moffett, Charlotte, Pathak, Nupur, Pathak, N., Parthsarathy, V., R Charlotte Moffett, O'Kane, M., Bjourson, Anthony J.   +30 more
core   +1 more source

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension

BMC Pulmonary Medicine, 2022
Background Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), can reduce cardiovascular events and mortality in patients with heart failure. A number of mechanisms have been proposed to explain the beneficial effects of SGLT2
Yi Tang, Siyuan Tan, Minqi Li, Yijin Tang, Xiaoping Xu, Qinghai Zhang, Qinghua Fu, Mingxiang Tang, Jin He, Yi Zhang, Zhaofen Zheng, Jianqiang Peng, Tengteng Zhu, Wenlin Xie   +13 more
doaj   +1 more source